Health care
We support clients in the healthcare industry by advising on emerging strategies and technologies, providing detailed diligence, and working with companies to deliver post-acquisition growth
“Innovation distinguishes between a leader and a follower”
— Steve Jobs
What we do.
The healthcare market is transforming. From ageing population to chronic illnesses - challenges in healthcare are mounting. But at the same time, innovation and digitalisation rise with them. Medicine is becoming more targeted, effective and patient-centric. Changing industry needs and ever-growing complexity represents significant opportunities for investment and growth.
We focus on supporting companies with the potential to grow and expand into new markets and value propositions. We help them challenge and shape their sectors by becoming more innovative, dynamic, and sustainable. Our practice areas reflect the rich diversity of the healthcare industry. We support clients in the healthcare industry by advising on emerging strategies and technologies, providing detailed diligence, and working with companies to deliver post-acquisition growth. We help to explore niche speciality areas that serve clients as platforms for future acquisitions and expansion. .
Biotech.
Breakthrough innovations in the human genome, material science, and molecular biology make the biotech industry more competitive than ever. We support companies in the areas of transplantation, regenerative medicine, and ageing by developing business strategies that position them to be more competitive and win investments for long-term growth.
Technologies continue to push the boundaries of how healthcare is diagnosed, monitored, and delivered. Digital transformation helps organisations to expand access to services and deliver a more effective patient and clinician experience. We work with entrepreneurs to catalyse the flow of funding and offer a unique perspective on value-creation pools.
Pharma.
M&A activity in the pharma industry has steadily increased as companies compete for innovative assets. We work with pharma with licencing and M&A teams to assess companies and pipeline products. We set up structured research to analyse the market landscape, threats and opportunities and engage with a range of industry stakeholders to validate the funding.
Growing cost puts pressure on the market access environment requiring innovative models to manage uncertainty, budget impact, and the sustainability of the healthcare system. We help pharma companies develop compelling value stories to demonstrate the clinical and economic benefits of assets. It helps to maximise the value for patients and the healthcare system and minimise risks for the organisation.